These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Mechanisms of sleep induction by GABA(A) receptor agonists.
    Author: Harrison NL.
    Journal: J Clin Psychiatry; 2007; 68 Suppl 5():6-12. PubMed ID: 17539703.
    Abstract:
    Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian central nervous system. GABA(A) receptors are pentameric complexes that function as ligand-gated chloride ion channels. Two types of inhibitory neurotransmission are mediated via GABA(A) receptors. Phasic inhibition results from the activation of receptors at the synapse by intermittent release of high concentrations of GABA from presynaptic terminals. Tonic inhibition, in contrast, is mediated by the continuous activation of receptors located outside the synaptic cleft by low concentrations of ambient GABA. These "extrasynaptic" receptors have a higher affinity for GABA and slower rates of desensitization and deactivation than do the classical "synaptic" receptors. A variety of subunit families make up GABA(A) receptors; a total of 19 distinct subunits have been cloned. This diversity in subunit composition results in substantial anatomical, functional, and pharmacologic heterogeneity. Receptors containing the alpha1, alpha2, or alpha3 subunits with gamma2 are usually found at synapses and are sensitive to benzodiazepines and zolpidem, whereas alpha4 and alpha6 subunits are often found with delta and play a role in extrasynaptic receptors (in thalamus and dentate), as does the alpha5 subunit (in CA1). The alpha4betadelta receptors are insensitive to benzodiazepines and zolpidem, but show high sensitivity to other sedative-hypnotic drugs, including ethanol and the novel hypnotic drug gaboxadol (THIP). This review will examine the role of heterogeneity of GABA(A) receptors, and recent research demonstrating subunit-dependent modulation of receptors by novel pharmacologic agents will be discussed.
    [Abstract] [Full Text] [Related] [New Search]